Adamas reports positive PII/III data for ADS-5102
This article was originally published in Scrip
Adamas Pharmaceuticals reported final Phase II/III data that show statistically significant improvements versus placebo in levodopa-induced dyskinesia (LID) for Parkinson's disease patients treated with ADS-5102 (Nurelin), an extended-release version of the generic Parkinson's drug amantadine.
You may also be interested in...
Some analysts see a 50-50 chance of US FDA approval despite the controversial dataset for the anti-amyloid antibody, but at least one expects an eventual CRL requesting a third Phase III trial.
A Phase I study for allogeneic therapy UCARTCS1A was put on clinical hold after a patient died. High dosing and double exposure to cyclophosphamide pre-conditioning may have played a role.
After accelerated approval in the US in April based on Phase II response rates, the company will seek full approval later this year based on a tripling of progression-free survival in a Phase III trial.